Treatment of children and adolescents with MDR/RR-TB regimens | Mathieu Bastard
Treatment of children and adolescents with MDR/RR-TB regimens containing bédaquiline and delamanid: results from the endTB observational study
Children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are under diagnosed and under treated. Few reports exist on the treatment of children and adolescents with newer TB drugs. The end-TB observational study assessed assessed the safety and effectiveness of MDR/RR-TB regimens containing bedaquiline and delamanid among children and adolescents.
Treatment of MDR/RR-TB with bedaquiline and delamanid is effective and well tolerated amongst children and adolescents. All oral regimens should be scaled up as recommended by WHO for these age groups.
